Here’s what you should know:
1. The FDA already approved Trulance to treat adults with chronic idiopathic constipation.
2. Researchers studied the drug’s effectiveness through two randomized, 12-week, double-blind, placebo-controlled trials. More than 2,100 patients received either a 3 mg or 6 mg dose of Trulance or a placebo. Synergy was only seeking approval for the 3 mg dose.
In both trials, Trulance met its primary endpoints with patients experiencing reduced abdominal pain and increased stool frequency as a result of the treatment.
3. Synergy Pharmaceuticals’ CEO Troy Hamilton said, “The IBS-C approval is a pivotal milestone for Synergy, representing the second approved indication for Trulance in the past 12 months. This approval demonstrates our unwavering commitment to provide a safe and effective treatment option for those patients living with these chronic GI disorders.”
More articles on gastroenterology:
Partnership offers Virginia practice access to clinical research services — 4 insights
19 GI physicians making headlines — December 2017
RedHill Biopharma, gMed & more — 10 GI company key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
